Moderna (MRNA) Other Non-Current Assets (2017 - 2026)

Moderna (MRNA) has reported Other Non-Current Assets for 10 consecutive years, with $618.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Assets rose 13.19% year-over-year to $618.0 million in Q2 2026; TTM through Jun 2026 was $618.0 million, a 13.19% increase from a year earlier, with the FY2025 full-year figure at $605.0 million, up 1.85% from the prior year.
• Other Non-Current Assets was $618.0 million for Q2 2026 at Moderna, down from $675.0 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $1.3 billion in Q2 2023 and troughed at $38.0 million in Q3 2022.
• A 5-year average of $613.1 million and a median of $611.5 million in 2025 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets surged 2047.83% in 2022 and sank 50.31% in 2024, its largest moves.
• Over 5 years, Other Non-Current Assets stood at $988.0 million in 2022, then declined by 22.47% to $766.0 million in 2023, then fell by 22.45% to $594.0 million in 2024, then rose by 1.85% to $605.0 million in 2025, then advanced by 2.15% to $618.0 million in 2026.
• The last three Other Non-Current Assets figures came in at $618.0 million (Q2 2026), $675.0 million (Q1 2026), and $605.0 million (Q4 2025), per Business Quant data.